Molecular Devices
Molecular Devices is a Danaher subsidiary that designs and sells bioanalytical instruments—including SpectraMax microplate readers, AI-powered high-content screening systems, automated cell culture platforms, and 3D organoid services—to pharmaceutical, biotechnology, academic, and CRO customers for drug discovery and complex biology research.
- Company typePrivate
- Founded1983
- HeadquartersSunnyvale, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Molecular Devices does
Molecular Devices, LLC is a life science instrumentation company operating as a wholly-owned subsidiary of Danaher Corporation within its Life Sciences segment. The company designs and manufactures bioanalytical measurement systems—including SpectraMax iD3s/iD5e multi-mode microplate readers, ImageXpress HCS.ai high-content screening systems, CellXpress.ai automated cell culture platforms, QPix FLEX microbial colony pickers, ClonePix mammalian colony pickers, and the ImageXpress Confocal HT.ai imaging system—used by pharmaceutical, biotechnology, academic core lab, contract research organization, and GxP-regulated laboratory customers for drug discovery, cell line development, toxicity assessment, and 3D biology research.
The company's underlying technology combines precision optical and liquid-handling hardware with an AI-driven software stack (IN Carta with SINAP deep learning segmentation and Phenoglyphs ML classification, MetaXpress acquisition/analysis software, SoftMax Pro control and GxP-compliance software) and consumable services, notably the 3D Ready Organoid Expansion Service built on proprietary bioreactor technology acquired through the December 2022 Cellesce acquisition. Underlying technical components include a Deep Tissue Confocal Spinning Disk module delivering a 4.5-fold signal-to-noise improvement for thick 3D samples, standardized automated workcells integrating Precise Automation PreciseFlex robots, Biosero Green Button Go scheduling, LiCONiC Wave STX44 incubators, Bionex HiG4 centrifuges, Beckman Coulter Biomek i7 liquid handlers, and AquaMax plate washers. Revenue derives from a mix of capital equipment sales (hardware), recurring software licensing and maintenance (SoftMax Pro, IN Carta, MetaXpress), organoid and consumable products and services (3D Ready expansion and standard PDOs), professional services (IQ/OQ/PM validation), and licensed biomarker workflow integration (Abcam co-development). Go-to-market relies on direct enterprise field sales staffed with application scientists, quote-based consultative pricing, conference presence (SLAS, ISSCR, synthetic biology events), and integration partnerships with the Automata LINQ lab automation platform and Beckman Coulter Life Sciences within the broader Danaher ecosystem.
Molecular Devices firmographics
Firmographics- Name
- Molecular Devices
- Legal name
- Molecular Devices, LLC
- Website
- https://moleculardevices.com
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Molecular Devices is a Danaher subsidiary that designs and sells bioanalytical instruments—including SpectraMax microplate readers, AI-powered high-content screening systems, automated cell culture platforms, and 3D organoid services—to pharmaceutical, biotechnology, academic, and CRO customers for drug discovery and complex biology research.
- Ownership category
- akta.pro rank
Molecular Devices industry classification
Industry- Product category
- Life Science Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Molecular Devices is headquartered
LocationHeadquarters
- HQ city
- Sunnyvale
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Molecular Devices business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Laboratory Instruments and Hardware: Sale of high-value laboratory instruments including microplate readers, high-content screening systems, automated cell culture systems, colony picking systems, and associated hardware. These are capital equipment purchases with typically multi-year lifecycles.
- Software Licenses and Subscriptions: Software products including IN Carta image analysis software, SoftMax Pro data analysis software, and MetaXpress HCI software. May include licensing fees and maintenance subscriptions.
- Organoid Products and Services: 3D Ready Organoid Expansion Service providing standardized, assay-ready organoids for drug discovery and research applications. Includes custom organoid production and expansion services.
- Service and Support: IQ/OQ/PM validation services, technical support, and laboratory automation solutions integration services for GMP/GLP compliant labs.
- Integrated Workflow Solutions: Partnership with Abcam for integrated biomarker discovery workflows combining validated assay kits, automation-ready microplate readers, and integrated data analysis software.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Molecular Devices product offering
Product offeringCore offering
Molecular Devices designs, manufactures, and sells high-performance bioanalytical measurement instruments, software, and automation systems used in life science research and drug discovery. Its portfolio spans microplate readers, high-content imaging systems, colony pickers, patch-clamp electrophysiology platforms, and automated cell culture systems, complemented by AI-powered image analysis and data acquisition software for pharmaceutical, biotechnology, and academic research customers.
Product overview
Molecular Devices is a life science instrumentation company offering a comprehensive portfolio of products for cellular analysis, drug discovery, and 3D biology research. The portfolio centers on SpectraMax microplate readers and SoftMax Pro GxP software for bioanalytical measurement; ImageXpress HCS.ai high-content screening systems with IN Carta AI-powered image analysis software for cellular imaging; CellXpress.ai automated cell culture system for 3D organoid workflows; QPix FLEX microbial colony picking and clone screening systems for cell line development; and the 3D Ready Organoid Expansion Service for scalable patient-derived organoid production. These products integrate through lab automation solutions including automated workcells combining instruments from Precise Automation, Biosero, Beckman Coulter Biomek, and LiCONiC, all connected via scheduling software. The company, a Danaher Corporation subsidiary, also offers GxP compliance solutions for regulated laboratories and operates an Organoid Innovation Center for collaborative research.
Differentiator
Problem solved
Functional benefit
Brands
- 3D Ready™: Organoid expansion service brand for scalable and consistent patient-derived organoids
- SpectraMax®
- ImageXpress®
- CellXpress.ai®
- QPix®
- ClonePix®
- CloneSelect®
- DispenCell™
- IN Carta®
- SoftMax® Pro
Products and services
- CellXpress.ai Automated Cell Culture System An AI-driven, GMP-ready automated cell culture system with integrated incubator, liquid handling, and on-deck imaging/analytics for cell line maintenance and expansion in biopharma.
- IN Carta Image Analysis Software Deep learning–based image analysis software for high-content screening, enabling phenotype classification, 3D organoid analysis, and AI-assisted data interpretation.
- 3D Ready Organoid Services Fee-for-service offering that cultures, screens, and analyzes patient-derived organoids for preclinical drug discovery and translational research customers.
- QPix Colony Picker Systems Automated microbial colony pickers that identify, pick, and re-array bacterial or yeast colonies at industrial throughput for synthetic biology and strain engineering.
- ImageXpress Confocal Microscopy System High-content confocal imaging system for 3D, live-cell, and phenotypic screening assays in drug discovery and cell biology research.
- SpectraMax Microplate Readers Multimode microplate readers for absorbance, fluorescence, luminescence, and other optical detection in biochemical and cell-based assays.
- FLIPR Penta System High-throughput kinetic cell-based screening system used to measure calcium flux and other rapid fluorescence responses in GPCR and ion channel drug discovery.
- Axon Patch-Clamp Systems Manual and automated patch-clamp electrophysiology instruments and consumables for ion channel research and cardiac safety screening.
- MetaXpress High-Content Image Analysis Software Image acquisition and analysis software that controls high-content screening instruments and quantifies phenotypic data.
- SoftMax Pro Software Data acquisition and analysis software for SpectraMax and other microplate readers, providing protocol control, curve fitting, and compliance-ready reporting.
Quantifiable outcome
- 4.5-fold improvement in signal-to-noise ratio for 3D organoid imaging
- +4 more outcomes
Companies that use Molecular Devices
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Molecular Devices technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration13 records
AI capability9 records
Feature10 records
Molecular Devices partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Beckman Coulter Life SciencescoreBoth Molecular Devices and Beckman Coulter Life Sciences (Danaher operating companies) are integrating their instruments with Automata's LINQ platform to create a unified ecosystem across multiple Danaher life sciences brands, eliminating manual bottlenecks in research workflows.
- AutomatacoreMolecular Devices partnered with London-based Automata to integrate its automated imaging and detection systems with Automata's LINQ platform, enabling connected, scalable, AI-ready research workflows. Danaher Ventures participated in Automata's Series C funding round and secured a board appointment. The collaboration also incorporates Beckman Coulter Life Sciences instruments, aiming to help scientific teams boost throughput and data quality while managing limited hands-on resources without added operational complexity.
- AbcamcorePartnership to provide integrated biomarker discovery workflows combining validated assay kits, automation-ready microplate readers, and integrated data analysis software. Collaboration tested in human ALT liver toxicity study demonstrating 4X more data with 60% less hands-on time compared to traditional approaches.
- Interim Diagnostic ImagingminorAcquisition expanded portfolio to include mobile CT, MRI, and PET scanners for rentals, complementing the existing imaging and detection product lines.
- CellescecoreAcquisition of Cardiff-based Cellesce specializing in large-scale production of patient-derived organoids (PDOs). Deal enabled creation of consistent human-derived organoids for high-throughput drug screening, potentially reducing drug development timelines. Cellesce's organoid production capabilities and expertise integrated into Molecular Devices' 3D Ready portfolio.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Molecular Devices competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Molecular Devices social profiles
Digital presenceMolecular Devices compliance and trust
Trust signalCompliance1 record
Molecular Devices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular Devices leadership team
Management profileNumber of profiles
Profiles5 records
Molecular Devices subsidiaries and ownership
Company hierarchySubsidiaries2 records
Molecular Devices funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular Devices M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular Devices
What does Molecular Devices do?
Molecular Devices designs, manufactures, and sells high-performance bioanalytical measurement instruments, software, and automation systems used in life science research and drug discovery. Its portfolio spans microplate readers, high-content imaging systems, colony pickers, patch-clamp electrophysiology platforms, and automated cell culture systems, complemented by AI-powered image analysis and data acquisition software for pharmaceutical, biotechnology, and academic research customers.
Is Molecular Devices a public or private company?
Molecular Devices is a private company. It is classified as corporate owned and is currently operating.
When was Molecular Devices founded?
Molecular Devices was founded in 1983. It employs 1,001 to 5,000 people.
Where is Molecular Devices based?
Molecular Devices is headquartered in Sunnyvale, United States, in the North America region.
How does Molecular Devices make money?
Five revenue lines are on record. Laboratory Instruments and Hardware is the primary driver. The others are software Licenses and Subscriptions, organoid Products and Services, service and Support and integrated Workflow Solutions.
Does Molecular Devices have an API?
No public API is recorded for Molecular Devices.
What industry is Molecular Devices in?
Molecular Devices's product category is Life Science Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 334516 and its SIC code is 3826.